ArticleFrontiers in physiology2026
The SGLT2i "canagliflozin" and the DPP-4i "sitagliptin" mitigate hypertensive nephropathy in adult male rats by modulating the Ang II/RAGE/Nox4/NLRP3 cascade.
Article in Frontiers in physiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hypertensive nephropathy (HN) with progressive renal damage is a common consequence of arterial hypertension (HTN). This study addresses the renoprotective attributes of the sodium-glucose cotransporter-2 inhibitor canagliflozin (Cana) and the dipeptidyl peptidase-4 inhibitor sitagliptin (Sita) on HN. Methods: Twenty-four adult male Wistar rats were categorized into four groups (six per group): control (CTRL), hypertensive nephropathy (HN); rats were given L-NAME (50 mg/kg, i.p., once a day), HN + Cana; rats were given L-NAME injections alongside oral Cana 10 mg/kg, and HN + Sita; rats were provided Sita 10 mg/kg concurrently with L-NAME injection. All regimens were given once a day for five consecutive weeks. Various physiological, biochemical, molecular, and histological parameters were evaluated. Results: Administration of Cana and Sita alleviated HN, as demonstrated by the notable improvements in renal functions, plasma angiotensin II, and systolic blood pressure. Additionally, a noticeable improvement in renal superoxide dismutase, malondialdehyde, NOD-like receptor family pyrin domain containing 3 inflammasome, interleukin (IL)-1β/-10, caspase 1, advanced glycation end products (AGEs), and relative expression of receptors for AGEs and nicotinamide adenine dinucleotide phosphate oxidase 4 was detected. Substantial enhancement in the microscopic structure of renal tissues, attenuated renal fibrosis, and decreased immunoreactivity of BAX and tumor necrosis factor-α highlighted these protective attributes. Conclusion: Both Sita and Cana successfully attenuated HTN and subsequent HN, thereby restoring renal function; however, Sita's protective profile was more favorable. These results implied that Sita and Cana might provide renoprotective impacts for kidney damage triggered by HTN in rats. However, additional research to investigate their possible modes of action is necessary.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.